AstraZeneca, Fasenra
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
AstraZeneca PLC AZN shares inched down 0.40% to £119.68 Tuesday, on what proved to be an all-around great trading session for ...
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...
An AstraZeneca immunotherapy improved survival rates in patients with bladder cancer, results that could reshape treatment of ...
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...
AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...
AstraZeneca Pharma India to launch Palivizumab in India, a drug to prevent RSV in high-risk children. Stocks rise.
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...
AstraZeneca PLC AZN shares inched up 0.74% to £120.16 Monday, on what proved to be an all-around positive trading session for ...
London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...
AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback